83
Participants
Start Date
May 26, 2020
Primary Completion Date
January 10, 2022
Study Completion Date
February 28, 2022
AT-527
One 550 mg tablet of AT-527 administered every \~12 hours (twice a day) for a total of 5 days
Placebo
One placebo tablet administered every \~12 hours (twice a day) for a total of 5 days
AT-527
Two 550 mg tablets of AT-527 administered every \~12 hours (twice a day) for a total of 5 days
Placebo
Two placebo tablets administered every \~12 hours (twice a day) for a total of 5 days
Atea Study Site, Washington D.C.
Atea Study Site, Charlotte
Atea Study Site, Columbia
Atea Study Site, Charleston
Atea Study Site, Atlanta
Atea Study Site, Orlando
Atea Study Site, Columbus
Atea Study Site, Cincinnati
Atea Study Site, Butte
Atea Study Site, Chicago
Atea Study Site, Chicago
Atea Study Site, Scottsdale
Atea Study Site, Los Angeles
Atea Study Site, Davis
Atea Study Site, Boston
Atea Study Site, Rosario
Atea Study Site, Vicente López
Atea Study Site, Brussels
Atea Study Site, Mechelen
Atea Study Site, Belo Horizonte
Atea Study Site, Brasília
Atea Study Site, Campo Largo
Atea Study Site, Porto Alegre
Atea Study Site, São Paulo
Atea Study Site, Cairo
Atea Study Site, Chisinau
Atea Study Site, Bucharest
Atea Study Site, Bloemfontein
Atea Study Site, Cape Town
Atea Study Site, Centurion
Atea Study Site, George
Atea Study Site, Worcester
Atea Study Site, Barcelona
Atea Study Site, Madrid
Atea Study Site, Pozuelo de Alarcón
Atea Study Site, Brovary
Atea Study Site, Kyiv
Lead Sponsor
Atea Pharmaceuticals, Inc.
INDUSTRY